- Home
- FRPH vs RAPT Comparison
FRPH vs RAPT Comparison
Compare FRPH & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | RAPT |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 498.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FRPH | RAPT |
|---|---|---|
| Price | $23.78 | $57.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $56.22 |
| AVG Volume (30 Days) | 54.8K | ★ 6.2M |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $33,049,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $97.41 | ★ N/A |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $21.68 | $5.67 |
| 52 Week High | $31.99 | $57.86 |
Technical Indicators
Market Signals| Indicator | FRPH | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 79.21 |
| Support Level | $23.33 | $57.61 |
| Resistance Level | $24.35 | $57.86 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | -0.03 | -0.72 |
| Stochastic Oscillator | 51.09 | 74.14 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.